THE DEAL, AT A GLANCE
From the announcementAulos Bioscience
01Who is involvedBacked by EcoR1 CapitalFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedAulos Bioscience raised $60M Series AFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersAulos Bioscience is financing an AI-designed IL-2 cancer immunotherapy program intended to move AB248 through Phase 1 solid tumor trials.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Aulos Bioscience · Financing Record
Explore source-linked visual explanations for Aulos Bioscience. Unsupported claims are withheld while source review continues.
Record 575 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →